Abstract:
One embodiment is a unique gas turbine engine combustion chamber including primary and secondary burning zones. Other embodiments include unique gas turbine engine apparatuses, systems, methods, and combinations.
Abstract:
The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.
Abstract:
A process for the extraction of uranium compounds from wet-process phosphoric acid includes lowering the iron concentration of the wet-process phosphoric acid and reducing the valency of any remaining ferric iron in the wet-process phosphoric acid to ferrous iron, and then extracting uranium compounds from the wet-process phosphoric acid. The process can include separating a side stream from a feed stream of wet-process phosphoric acid, wherein the side stream has a greater concentration of the uranium compounds than the feed stream by filtration. Extracting uranium compounds from the wet-process phosphoric acid can be by ion exchange process or by solvent extraction.
Abstract:
In a preferred embodiment, a process for extracting uranium from wet-process phosphoric acid (WPA), comprises separating uranium from WPA to produce a loaded uranium solution stream and a uranium depleted WPA stream. The loaded uranium solution stream is then contacted by with an ion exchange resin. Uranium species bound to the ion exchange resin are eluted by contacting the resin with a solution comprising anions to produce a loaded uranium eluant stream. The loaded uranium eluant stream is treated to provide a uranium containing product.
Abstract:
One embodiment is a unique gas turbine engine combustion chamber including primary and secondary burning zones. Other embodiments include unique gas turbine engine apparatuses, systems, methods, and combinations.
Abstract:
A process for the extraction of uranium compounds from wet-process phosphoric acid includes lowering the iron concentration of the wet-process phosphoric acid and reducing the valency of any remaining ferric iron in the wet-process phosphoric acid to ferrous iron, and then extracting uranium compounds from the wet-process phosphoric acid. The process can include separating a side stream from a feed stream of wet-process phosphoric acid, wherein the side stream has a greater concentration of the uranium compounds than the feed stream by filtration. Extracting uranium compounds from the wet-process phosphoric acid can be by ion exchange process or by solvent extraction.
Abstract:
This invention relates to use of proteins associated with chronic tissue damage, e.g., chronic dermal ulcers. The proteins identified are useful for clinical screening, diagnosis, prognosis, therapy, and prophylaxis, as well as for drug screening and drug development.
Abstract:
The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.
Abstract:
This invention relates to use of proteins associated with chronic tissue damage, e.g., chronic dermal ulcers. The proteins identified are useful for clinical screening, diagnosis, prognosis, therapy, and prophylaxis, as well as for drug screening and drug development.